Publication Name	World Journal of Gastroenterology
Manuscript ID	6395
Country	China

Received	2013-10-16 11:30
Peer-Review Started	2013-10-16 17:42
First Decision by Editorial Office Director
Return for Revision	2013-12-18 10:34
Revised	2014-01-13 16:48
Publication Fee Transferred
Second Decision by Editor	2014-02-27 11:18
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-02-27 11:31
Articles in Press
Edit the Manuscript by Language Editor	2014-03-19 21:23
Typeset the Manuscript	2014-04-14 16:20
Publish the Manuscript Online	2014-04-29 09:53

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Entecavir vs lamivudine therapy for naive patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure
Manuscript Source	Invited Manuscript
All Author List	Yang Zhang, Xiao-Yu Hu, Sen Zhong, Fang Yang, Tao-You Zhou, Guo Chen, Yan-Yan Wang and Jian-Xing Luo
Funding Agency and Grant Number	Funding Agency Grant Number National Key Technology R&D Program of China during the 10th Five-Year Plan Period 2008ZX10005 National Key Technology R&D Program of China during the 10th Five-Year Plan Period 2009ZX10005
Corresponding Author	Xiao-Yu Hu, Professor, Department of Infectious Diseases, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 39 Shierqiao Road, Chengdu 610072, Sichuan Province, China. xiaoyuhu@aliyun.com
Key Words	Acute-on-chronic liver failure; Hepatitis B; Entecavir; Lamivudine; Survival
Core Tip	This study compared the short-term and long-term efficacy of entecavir and lamivudine in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure (ACLF). Entecavir significantly reduced hepatitis B virus DNA levels, decreased the Child-Turcotte-Pugh and model for end-stage liver disease (MELD) scores, and thereby improved the long-term survival rate in patients with spontaneous reactivation of hepatitis B presenting as ACLF. Pretreatment MELD score and virological response at 30 d were good predictors of long-term survival.
Publish Date	2014-04-29 09:53
Citation	Zhang Y, Hu XY, Zhong S, Yang F, Zhou TY, Chen G, Wang YY, Luo JX. Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol 2014; 20(16): 4745-4752
URL	http://www.wjgnet.com/1007-9327/full/v20/i16/4745.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i16.4745

Full Article (PDF)	WJG-20-4745.pdf
Full Article (Word)	WJG-20-4745.doc
Manuscript File	6395-Review.doc
Answering Reviewers	6395-Answering reviewers.pdf
Copyright License Agreement	6395-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	6395-Language certificate.PDF
Peer-review Report	6395-Peer review(s).pdf
Scientific Editor Work List	6395-Scientific editor work list.doc